MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 89 filers reported holding MARINUS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,463,328 | -24.4% | 430,227 | +2.0% | 0.00% | 0.0% |
| Q2 2023 | $4,581,226 | +758.4% | 421,844 | +445.4% | 0.00% | – |
| Q1 2023 | $533,667 | +76.3% | 77,343 | +1.7% | 0.00% | – |
| Q4 2022 | $302,786 | -20.3% | 76,077 | +33.5% | 0.00% | – |
| Q3 2022 | $380,000 | +37.2% | 57,003 | -0.1% | 0.00% | – |
| Q2 2022 | $277,000 | -90.7% | 57,083 | -82.1% | 0.00% | -100.0% |
| Q1 2022 | $2,978,000 | -25.1% | 318,577 | -4.9% | 0.00% | 0.0% |
| Q4 2021 | $3,978,000 | +3.5% | 334,910 | -0.9% | 0.00% | 0.0% |
| Q3 2021 | $3,845,000 | -40.7% | 337,801 | -6.5% | 0.00% | 0.0% |
| Q2 2021 | $6,483,000 | +34.1% | 361,393 | +15.7% | 0.00% | 0.0% |
| Q1 2021 | $4,833,000 | +38.3% | 312,221 | +9.0% | 0.00% | 0.0% |
| Q4 2020 | $3,494,000 | -4.0% | 286,398 | +1.2% | 0.00% | 0.0% |
| Q3 2020 | $3,638,000 | – | 283,090 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |